D. Scott McMeekin, MD
Professor, Section Chief, Gynecologic Oncology
The University of Oklahoma
800 NE 10th St
Suite 5050
Oklahoma City,
OK
USA
73104
Papers:
11 - Focused Plenary
Molecular profiling of tumors from stage I versus stage III/IV cancer patients: a prediction signature for metastasis in Gynecologic Oncology Group 8024
120 - Featured Poster
The influence of obesity on disease characteristics and survival among patients with epithelial ovarian cancer
164 - Poster Session A
Adenocarcinoma indicates more favorable prognosis with cervix cancer
224 - Poster Session A
Characterization of primary platinum resistance in an era of biologic agents and novel chemotherapeutic design
240 - Poster Session A
Venous thromboembolism carries a particularly grave prognosis with epithelial ovarian cancer
251 - Poster Session A
Acquired platinum resistance among women with high-grade serous epithelial ovarian cancer
302 - Poster Session A
Expression profiles of LKB1/AMPK in endometrial cancer specimens as a potential biomarker for targeted metabolic drug therapy
334 - Poster Session A
Proteomic profiling of stage I endometrial cancers: a signature of early-stage recurrence in GOG 8016
367 - Poster Session B
Analysis of patients referred to an academic gynecologic oncology clinic with an OVA1 test
431 - Poster Session B
Measurements of adiposity as predictive biomarkers for response to first-line bevacizumab-based chemotherapy in epithelial ovarian cancer (EOC)
Late Breaking Abstract 1
A Randomized Phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): A Gynecologic Oncology Group tr